<DOC>
	<DOC>NCT00371345</DOC>
	<brief_summary>This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer</brief_summary>
	<brief_title>Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>females, 18 or older recurrent, locally advanced, or metastatic breast cancer with expression of ER/PR receptor and/or overexpression of Her2/neu paraffinembedded tissue block must be available measurable disease prior chemotherapy with an anthracycline and/or a taxane (neoadjuvant, adjuvant, or metastatic setting) 0, 1 or 2 chemotherapies in the metastatic setting adequate organ function Metastatic disease confined to bone only Symptomatic central nervous system (CNS) metastasis Concurrent medical condition which may increase the risk of toxicity Unable to take oral medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Recurrent, locally-advanced, or metastatic breast cancer</keyword>
</DOC>